Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from NLS Pharmaceutics ( (NLSP) ) is now available.
On September 30, 2025, NLS Pharmaceutics announced that its shareholders approved a merger with Kadimastem at an Extraordinary General Meeting held on September 29, 2025. This merger, pending final Nasdaq approval, will create NewCelX Ltd., a Nasdaq-listed biotechnology company. The merger combines NLS’s expertise in CNS small-molecule therapies with Kadimastem’s advanced cell therapy programs, including a Phase 2a ALS study and a diabetes program. The combined company aims to leverage a diversified pipeline and experienced leadership to drive long-term growth and deliver transformative therapies.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company that focuses on developing innovative therapies for central nervous system disorders. Kadimastem Ltd. is a clinical-stage cell therapy company specializing in treatments for neurodegenerative diseases and diabetes.
Average Trading Volume: 219,570
Technical Sentiment Signal: Sell
Current Market Cap: $10.42M
Learn more about NLSP stock on TipRanks’ Stock Analysis page.